Novocure Ltd

NVCR remains in a Stage 4 decline, confirmed by persistent lower highs and lower lows under downtrending EMAs. The active Lower Highs & Lower Lows pattern indicates supply dominance and keeps the medium-term bias bearish. Price recently rallied into declining EMAs and was rejected, signaling fresh selling pressure. Short-term timing favors initiating bearish execution now into the EMA resistance zone, with failure to break above reinforcing continued downside potential.

• ↑168 Optune Pax prescriptions and 90 active patients in first month
• ↑Q1 net revenue $174M (+12% YoY), Germany added $2.5M
• ↓Negative earnings yield and weak profitability factors signal poor returns